The Short Answer
One Hormone Pathway or Two
Wegovy® acts on the GLP-1 receptor. Zepbound® acts on both the GIP and GLP-1 receptors, as its label describes it.
Different Extra Uses
Beyond weight reduction, Wegovy® is approved to lower heart event risk in adults with heart disease and for a liver condition called MASH. Zepbound® is also approved for moderate to severe obstructive sleep apnea in adults with obesity.
A Published Head-to-Head Trial
In SURMOUNT-5, one open-label trial, adults with obesity lost an average of 20.2% of body weight on tirzepatide and 13.7% on semaglutide over 72 weeks. Averages are not promises, and the trial has limits covered below.
Shot or Tablet
Zepbound® is a once-weekly injection. Wegovy® comes as a once-weekly injection or a once-daily tablet, each with its own steps on the same label.
Wegovy® and Zepbound® at a Glance
One row per label fact, from the Wegovy® and Zepbound® prescribing information.
| Wegovy® | Zepbound® | |
|---|---|---|
| Ingredient | Semaglutide | Tirzepatide |
| Maker | Novo Nordisk | Eli Lilly |
| Receptors | GLP-1 | GIP and GLP-1 |
| Approved uses | Weight reduction (adults; children 12+ for the injection); heart risk reduction; MASH (injection) | Weight reduction (adults); obstructive sleep apnea in adults with obesity |
| Forms | Weekly injection (pens, syringes, FlexTouch); daily tablet | Weekly injection: single-dose pen or vial, multi-dose vial or KwikPen |
Approved Uses in Full
Wegovy® injection is approved for weight reduction in adults and in children 12 and older with obesity, and in adults with overweight and a weight-related condition. It is also approved for heart event risk reduction in adults with heart disease and obesity or overweight, and for MASH with moderate to advanced liver scarring.
Zepbound® is approved for weight reduction in adults with obesity, or overweight with at least one weight-related condition. It is also approved for moderate to severe obstructive sleep apnea in adults with obesity.
Forms and How Often
Zepbound® comes in single-dose pens, single-dose vials, multi-dose vials or a multi-dose KwikPen, taken once a week. Wegovy® injection comes in single-dose pens, single-dose syringes or a multi-dose FlexTouch pen once a week, and Wegovy® tablets are taken once a day on an empty stomach.
The Diabetes Brands With the Same Ingredients
Semaglutide is also sold as Ozempic® and tirzepatide as Mounjaro®, each with its own diabetes label. The Mounjaro® vs Ozempic® comparison covers those two.
Who Should Not Use Either One
Both labels rule out anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2. Both also rule out a known allergy to the active ingredient or the product's other ingredients.
Using Them Together
Both labels say combining the medicine with any other GLP-1 receptor agonist is not recommended. Wegovy® and Zepbound® are not meant to be taken together.
What the SURMOUNT-5 Trial Found
Every figure is a group average from one open-label trial at 72 weeks.
| Average result, 72 weeks, one open-label trial | Tirzepatide | Semaglutide |
|---|---|---|
| Doses studied (highest tolerated) | 10 mg or 15 mg weekly | 1.7 mg or 2.4 mg weekly |
| Average body weight change | -20.2% | -13.7% |
| Average waist change | -18.4 cm | -13.0 cm |
How the Trial Was Set Up
SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes to the highest dose they could tolerate of tirzepatide, 10 mg or 15 mg, or semaglutide, 1.7 mg or 2.4 mg, once weekly for 72 weeks. Results were published in the New England Journal of Medicine in July 2025.
Weight and Waist Results
Average weight fell by 20.2% on tirzepatide and 13.7% on semaglutide. Average waist size fell by 18.4 cm and 13.0 cm, and more people on tirzepatide reached 10%, 15%, 20% and 25% weight reductions.
Side Effects in the Trial
The most common side effects in both groups were stomach-related. Most were mild to moderate and happened mainly while the dose was being raised.
What the Trial Does Not Tell You
The trial was open-label, funded by Eli Lilly, and did not include people with type 2 diabetes. Averages describe groups, not you, so bring these numbers to your prescriber rather than treating them as a verdict.
Dose Steps Listed on Each Label
Quoted from the FDA labels so the numbers make sense. These are each label's own schedule, not a recommendation or a plan for you.
Wegovy® Injection Steps
The Wegovy® label lists 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12 and 1.7 mg for weeks 13 to 16. For adult weight reduction the maintenance step is 1.7 mg or 2.4 mg, with 2.4 mg recommended and 7.2 mg listed as a maximum for some adults.
Wegovy® Tablet Steps
Wegovy® tablets start at 1.5 mg once daily for 30 days, then 4 mg and 9 mg for 30 days each. From day 91 the label lists 25 mg once daily as the maintenance dosage.
Zepbound® Steps
The Zepbound® label starts at 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks on each dose. The maintenance dose for weight reduction is 5 mg, 10 mg or 15 mg, and 15 mg is the maximum.
Why the Milligram Numbers Can't Be Compared
Semaglutide and tirzepatide are different molecules, and milligram amounts of different molecules can't be compared. There is no conversion between them, and your prescriber sets every step.
Common Side Effects on Each Label
Placebo-controlled numbers from each label's weight-reduction trials, each read against its own placebo.
| Side effect | Wegovy® 2.4 mg vs placebo | Zepbound® vs placebo |
|---|---|---|
| Nausea | 44% vs 16% | 25-29% vs 8% |
| Diarrhea | 30% vs 16% | 19-23% vs 8% |
| Constipation | 24% vs 11% | 11-17% vs 5% |
| Vomiting | 24% vs 6% | 8-13% vs 2% |
| Stomach pain | 20% vs 10% | 9-10% vs 5% |
| Stopped because of side effects | 6.8% vs 3.2% | 4.8-6.7% vs 3.4% |
How Many People Stopped
About 6.8% of people on Wegovy® 2.4 mg stopped because of side effects, compared with 3.2% on placebo. On Zepbound®, 4.8% to 6.7% stopped depending on dose, compared with 3.4% on placebo.
Why the Label Tables Differ
Each label's numbers come from its own trials with different people and doses. They show what each label reports, not how one person would feel on each.
Full Breakdowns for Each Brand
The GLP-1 side effects guide sets out both labels' full tables and the warning signs to act on.
Track Either Medicine in Pep AI
Once the prescriber decides, the daily work begins.
Quick Logging and Site Rotation
Pep AI logs a weekly Wegovy® or Zepbound® shot in a couple of taps, or a daily tablet with its own schedule, along with step-ups. The body map shows where your recent shots went, so rotating sites is simple. See the Wegovy® tracker and the Zepbound® tracker.
Reminders on Your Lock Screen
Pep AI sends shot-day reminders that show on your Lock Screen, and a daily tablet gets its own schedule. On iPhone, home-screen widgets, a Lock Screen Live Activity and an Apple Watch app show what is due at a glance.
Symptoms, Day by Day
Pep AI's side-effect log has a built-in list of GLP-1 symptoms, plus your own, each rated for severity on the day you log it. Your dose history keeps its dates too, so you can check a rough patch against when your step changed.
Protein and Fiber on Small Portions
Pep AI logs meals by photo scan, barcode, restaurant menu scan or search and puts estimated protein, fiber and water first. Smaller appetites still need enough of each, and your daily goals keep that in view. More in the protein tracker.
Your Weight Trend Over Months
Pep AI keeps your weight trend and progress photos together, and can read weight from Apple Health on iPhone or Health Connect on Android. The line shows months of change, not one morning on the scale.
Key takeaways
- Wegovy® (semaglutide) acts on GLP-1; Zepbound® (tirzepatide) acts on GIP and GLP-1. Both labels cover long-term weight reduction.
- Wegovy® adds heart risk reduction and MASH; Zepbound® adds obstructive sleep apnea in adults with obesity.
- In SURMOUNT-5, an open-label Lilly-funded trial without people with diabetes, average weight loss at 72 weeks was larger with tirzepatide.
- Milligram amounts of different molecules can't be compared. They are not taken together.
- Which medicine and any switch are your prescriber's decision.
Whatever your prescriber decides, keep the record.
Doses, side effects, meals and weight for any GLP-1 brand, in one app. Pep AI is free to try on iPhone and Android: a free download with a 3-day free trial, then a subscription.
Frequently asked questions
Keep reading
Sources
- Wegovy® (semaglutide) prescribing information and Medication Guide, Novo Nordisk / FDA (revised 06/2026)
- Zepbound® (tirzepatide) prescribing information and Medication Guide, Eli Lilly / FDA (revised 08/2026)
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36
This page compares FDA prescribing information and published trials for general information. It is not medical advice and does not tell you which medicine or dose to take; that decision belongs to you and your prescriber. Dose steps are quoted from each label's own schedule, not as a plan for you. Pep AI is not affiliated with Novo Nordisk or Eli Lilly, and brand names are trademarks of their owners. If a symptom is severe or worrying you, contact your healthcare provider. In an emergency, call 911.
Published by the Pep AI team · Updated November 2026